Procyon Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Procyon Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3	Closed	–	–	732
2020 Q2	$0	Hold	3	–	–	﹤0.01%	1150
2020 Q1	$0	Hold	3	–	–	﹤0.01%	1106
2019 Q4	$0	Buy	+3	New	+$314	﹤0.01%	1044

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Procyon Advisors's NBIX Position: Q3 2020 in Review

Procyon Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 3 shares.

Procyon Advisors first reported a position in NBIX in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

Procyon Advisors reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
Procyon Advisors sold 3 Neurocrine Biosciences shares in Q3 2020.
Procyon Advisors first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 3 quarters.
Procyon Advisors's Neurocrine Biosciences position peaked at $0 in Q2 2020.
418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.